Nicole E. Follmer, Ph.D. - Publications

Affiliations: 
2012 Biology: Medical Sciences, Division of Harvard University, Cambridge, MA, United States 
Area:
Biochemistry, Molecular Biology

5/10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Follmer NE, Wani AH, Francis NJ. A polycomb group protein is retained at specific sites on chromatin in mitosis. Plos Genetics. 8: e1003135. PMID 23284300 DOI: 10.1371/Journal.Pgen.1003135  0.84
2012 Follmer NE, Francis NJ. Preparation of Drosophila tissue culture cells from different stages of the cell cycle for chromatin immunoprecipitation using centrifugal counterflow elutriation and fluorescence-activated cell sorting. Methods in Enzymology. 513: 251-69. PMID 22929773 DOI: 10.1016/B978-0-12-391938-0.00011-2  0.84
2012 Lo SM, Follmer NE, Lengsfeld BM, Madamba EV, Seong S, Grau DJ, Francis NJ. A bridging model for persistence of a polycomb group protein complex through DNA replication in vitro. Molecular Cell. 46: 784-96. PMID 22749399 DOI: 10.1016/J.Molcel.2012.05.038  0.84
2011 Follmer NE, Francis NJ. Speed reading for genes: bookmarks set the pace. Developmental Cell. 21: 807-8. PMID 22075142 DOI: 10.1016/J.Devcel.2011.10.020  0.84
2009 Francis NJ, Follmer NE, Simon MD, Aghia G, Butler JD. Polycomb proteins remain bound to chromatin and DNA during DNA replication in vitro. Cell. 137: 110-22. PMID 19303136 DOI: 10.1016/J.Cell.2009.02.017  0.84
Low-probability matches
2021 Quiroz RV, Reutershan MH, Schneider SE, Sloman D, Lacey BM, Swalm BM, Yeung CS, Gibeau C, Spellman DS, Rankic DA, Chen D, Witter D, Linn D, Munsell E, Feng G, ... ... Follmer NE, et al. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry. PMID 33755451 DOI: 10.1021/acs.jmedchem.0c02083  0.01
2017 Conery AR, Centore RC, Spillane KL, Follmer NE, Bommi-Reddy A, Hatton C, Bryant BM, Greninger P, Amzallag A, Benes CH, Mertz JA, Sims RJ. Abstract B19: Targeting dependencies within apoptotic pathways through inhibition of BET bromodomains Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B19  0.01
2016 Conery AR, Centore RC, Spillane KL, Follmer NE, Bommi-Reddy A, Hatton C, Bryant BM, Greninger P, Amzallag A, Benes CH, Mertz JA, Sims RJ. Preclinical anticancer efficacy of BET bromodomain inhibitors is determined by the apoptotic response. Cancer Research. PMID 26759243 DOI: 10.1158/0008-5472.Can-15-1458  0.01
2014 Follmer N, Mertz J, Conery A, Bryant B, Hatton C, Centore R, Huang H, Spillane K, Sims R. Abstract 2327: Defining the determinants of sensitivity and resistance to BET bromodomain inhibition Cancer Research. 74: 2327-2327. DOI: 10.1158/1538-7445.Am2014-2327  0.01
2014 Mertz J, Huang H, Follmer N, Reddy A, Centore R, Bryant B, Hatton C, Franco H, Krause W, III RS. 581 Identification of genomic and chromatin features that predict transcriptional response to BET bromodomain inhibition European Journal of Cancer. 50: 187-188. DOI: 10.1016/S0959-8049(14)70707-5  0.01
Hide low-probability matches.